Table 1 Characteristics of the study cohorts
Cohort | Covid-19 | Acute heart failure | Myocardial infarction | Stroke |
|---|---|---|---|---|
Cohort size | ||||
 Pre exclusion | 3948 | 3355 | 5560 | 3324 |
 Post exclusion | 3650 | 2897 | 4524 | 2877 |
Demographics | ||||
 Age - yrs | 61.8 (47.4–75.9) | 74.2 (63.7–83.1) | 68.9 (59.1–78.6) | 70.7 (57.8–82.0) |
 Gender - % male | 56.00% | 58.60% | 64.20% | 55.70% |
 Self-reported Race -% white | 58.90% | 78.60% | 76.70% | 78.50% |
 Self-reported Ethnicity - % hispanic | 18.00% | 8.00% | 8.40% | 7.30% |
Biomarkers | ||||
 White blood cells (WBC) - ×103/µL | 6.96 (5.19–9.49) | 8.57 (6.66–11.11) | 9.33 (7.19–12.25) | 9.19 (7.02–12.42) |
 Platelets (PLT) - ×103/µL | 212 (164–274) | 214 (165–273) | 225 (181–276) | 212 (168–266) |
 Red cell distribution width (RDW) - % | 13.5 (12.7–14.8) | 15.1 (13.9–16.8) | 13.6 (12.9–14.8) | 13.5 (12.8–14.6) |
 Abs lymphocytes (ALYMPH) - ×103/µL | 1.05 (0.69–1.56) | 1.20 (0.82–1.75) | 1.60 (1.05–2.32) | 1.38 (0.94–2.05) |
 Abs monocytes (AMONO) - ×103/µL | 0.55 (0.37–0.78) | 0.69 (0.53–0.91) | 0.70 (0.52–0.93) | 0.66 (0.5–0.89) |
 Abs neutrophils (ANEUT) - ×103/µL | 4.94 (3.41–7.09) | 6.18 (4.50–8.47) | 6.34 (4.52–9.09) | 6.50 (4.56–9.66) |
Ratios | ||||
 Platelet-white cell (PWR) | 30.8 (22.5–40.4) | 25.1 (18.7–32.8) | 24.1 (18.2–31.5) | 22.5 (16.4–30.2) |
 Monocyte-to-lymphocyte (MLR) | 0.50 (0.31–0.81) | 0.57 (0.38–0.86) | 0.42 (0.28–0.68) | 0.47 (0.3–0.74) |
 Neutrophil-to-lymphocyte (NLR) | 4.71 (2.68–8.17) | 5.00 (3.12–8.41) | 3.87 (2.26–7.41) | 4.61 (2.53–8.65) |
 Platelet-to-lymphocyte (PLR) | 196.4 (131.9–304.7) | 174.3 (115.3–264.2) | 138.1 (95.7–211.8) | 149.6 (99.5–224.1) |
 RDW-to-platelet (RPR) | 0.06 (0.05–0.08) | 0.07 (0.05–0.09) | 0.06 (0.05–0.08) | 0.06 (0.05–0.08) |
Outcomes | ||||
 30-day post-discharge, all-cause mortality | 8.80% | 8.70% | 7.40% | 14.00% |
